06/27/2026
https://pubmed.ncbi.nlm.nih.gov/42203321/
In this prospective real-world cohort of patients with cancer, ivermectin and mebendazole were associated with high rates of self-reported clinical benefit and favorable tolerability. These findings are hypothesis-generating and support the need for randomized controlled trials.